Mechanism Based In Vitro Assays for Antifibrotic Drug Discovery

Fibrosis is a final common pathological end-point of chronic injury in multiple organs, characterized by persistent myofibroblast activation, excessive extracellular matrix (ECM) deposition, and progressive organ dysfunction. Although triggers differ across pulmonary, hepatic, renal, cardiac, and dermal fibrosis, a conserved set of cellular and molecular mechanisms drives disease progression. Translational research has increasingly focused on these shared pathways to identify broad-acting therapeutic targets and develop cell-based assays to screen potential antifibrotic compounds. This review integrates mechanistic insights, and scalable in vitro screening platforms that are applicable across fibrotic indications.

The Burden and Biology of Fibrotic Diseases

Fibrotic diseases represent a major global health burden, encompassing conditions such as idiopathic pulmonary fibrosis (IPF), metabolic dysfunction-associated steatohepatitis (MASH) with liver fibrosis, chronic kidney disease (CKD), systemic sclerosis (SSc), and cardiac fibrosis. Regardless of the initiating insult, whether persistent inflammation, metabolic stress, mechanical injury, or autoimmune dysfunction, fibrosis is defined by excessive ECM accumulation leading to architectural distortion and organ failure. While organ-specific aspects exist, a convergent set of cellular states and signaling networks characterize the fibroproliferative response across tissues, providing opportunities for cross-disease therapeutic strategies.

Shared Cellular and Molecular Mechanisms Across Fibrotic Diseases

Despite diverse initiating insults and organ-specific contexts, fibrotic diseases converge on a highly conserved cellular and molecular program that governs tissue remodeling, architectural distortion, and progressive organ dysfunction. Central to this program is the emergence, expansion, and persistence of activated myofibroblasts, accompanied by excessive extracellular matrix (ECM) deposition, sustained profibrotic signaling, immune reprogramming, parenchymal cell dysfunction, mechano-transductive reinforcement, apoptosis resistance, and failure of resolution pathways. Together, these interconnected processes establish a self-perpetuating fibrotic niche that distinguishes pathological fibrosis from physiological wound repair.

A universal hallmark of fibrosis is the differentiation and persistence of α-smooth muscle actin (α-SMA)–positive myofibroblasts.  Myofibroblasts are the principal effector cells responsible for matrix production and tissue contraction. These cells exhibit robust expression of α-SMA, heightened synthesis of type I and III collagens, secretion of fibronectin and other ECM components, and acquisition of a contractile phenotype that contributes to tissue stiffening and distortion. Myofibroblasts are also characterized by resistance to apoptosis and sustained autocrine profibrotic signaling, particularly via Transforming Growth Factor beta (TGF-β). Importantly, they arise from multiple cellular sources, including resident fibroblasts, pericytes, epithelial or endothelial cells undergoing partial epithelial–mesenchymal or endothelial–mesenchymal transition, and circulating fibrocytes. Regardless of origin, the convergence point across fibrotic diseases is persistent myofibroblast survival beyond the temporal window of normal wound healing.

Concomitant with myofibroblast expansion is excessive ECM deposition. All fibrotic tissues demonstrate accumulation of fibrillar collagens, predominantly types I and III, along with increased fibronectin, and elevated matricellular proteins. Enhanced expression and activity of crosslinking enzymes, including Lysyl Oxidase Like 2 (LOXL2), further stabilize and stiffen the matrix. These structural changes produce profound biomechanical consequences: tissue stiffening, altered mechano-transduction, and progressive loss of normal parenchymal architecture. The remodeled matrix not only reflects fibrosis but actively propagates it.

Conserved profibrotic signaling sustains the remodeling program. Dominant TGF-β signaling integrates upstream injury cues and orchestrates transcriptional programs that drive fibroblast activation and ECM production. Parallel activation of Platelet-Derived Growth Factor (PDGF) pathways promotes fibroblast proliferation and survival, while type 2 cytokines such as Interleukin 13 (IL-13) further reinforce matrix synthesis and immune–stromal crosstalk. Mechanosensitive transcriptional regulators, particularly Yes-associated protein (YAP) and its paralog TAZ, respond to matrix stiffening and amplify profibrotic gene expression. Collectively, these signaling networks sustain fibroblast activation, establish feed-forward ECM production loops, and reduce the likelihood of reversion to a quiescent mesenchymal state.

Macrophage reprogramming represents another shared axis of fibrosis. Across pulmonary, hepatic, renal, and cardiac contexts, there is expansion of alternatively activated (M2-like) macrophages that secrete TGF-β, PDGF, and other growth factors. Over time, macrophages transition from predominantly inflammatory phenotypes toward profibrotic states that directly stimulate fibroblast activation through paracrine signaling loops. This dynamic immune–stromal interplay reinforces matrix deposition and contributes to the chronicity of the fibrotic response.

Underlying these stromal and immune changes is persistent epithelial or endothelial dysfunction. Repeated injury and incomplete repair compromise barrier integrity and promote aberrant regenerative responses. Injured parenchymal cells frequently adopt a senescence-associated secretory phenotype (SASP), characterized by secretion of proinflammatory and profibrotic mediators that perpetuate stromal activation. Cellular senescence has emerged as a shared feature in diverse fibrotic disorders, including idiopathic pulmonary fibrosis, metabolic liver fibrosis, chronic kidney disease, and systemic sclerosis, underscoring its role in linking epithelial injury to mesenchymal expansion.

A defining feature that distinguishes fibrosis from transient repair is the establishment of mechanical memory. Progressive ECM stiffening activates integrins and cytoskeletal tension pathways, leading to stabilization of profibrotic transcriptional programs. As fibroblasts adapt to stiffened matrices, they become mechanically “locked” in an activated state, maintaining collagen production even if the initiating injury subsides. This mechano-transductive reinforcement creates a self-sustaining fibrotic niche that perpetuates disease independently of the original insult.

Myofibroblast persistence is further supported by resistance to apoptosis. Fibrotic fibroblasts commonly display reduced mitochondrial apoptotic signaling, increased activation of pro-survival pathways such as PI3K/AKT and ERK, and diminished sensitivity to death receptor signaling. This survival advantage enables their continued presence well beyond the timeframe of physiological wound healing, fundamentally distinguishing pathological fibrosis from normal tissue repair, in which myofibroblasts undergo timely clearance.

Finally, fibrosis is marked by impaired resolution pathways. Antifibrotic mediators are reduced, matrix degradation is insufficient, and the balance between matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) is disrupted in favor of ECM accumulation. In contrast to normal wound healing, where coordinated matrix deposition and degradation restore tissue integrity, fibrosis represents a failure of resolution, culminating in irreversible structural remodeling.

Taken together, these conserved cellular features define a unified pathological program shared across fibrotic diseases. This convergence provides a conceptual framework for the development of cross-organ therapeutic strategies targeting the core fibrotic cell state rather than organ-specific manifestations alone.

Shared Therapeutic Targets Across Fibrotic Diseases

Fibrotic diseases across multiple organs converge on a set of shared cellular and molecular drivers. Fibrosis is orchestrated by conserved signaling networks. Therapeutic strategies aimed at these core pathways therefore have broad applicability, targeting mechanisms that are common to essentially all fibrotic conditions rather than being organ-specific.

The TGF-β / SMAD pathway represents a central hub of fibroblast activation and ECM production. Therapeutic interventions include ligand sequestration with neutralizing antibodies, receptor kinase inhibition, and downstream transcriptional modulators that reduce SMAD-mediated profibrotic gene expression. Agents such as Fresolimumab and Galunisertib exemplify approaches targeting this pathway. Inhibition of TGF-β signaling is expected to decrease myofibroblast differentiation, reduce collagen deposition, and limit ECM remodeling. However, systemic blockade carries potential risks due to TGF-β’s essential roles in immune homeostasis and cell proliferation.

Integrins and ECM activation constitute another conserved node. αv integrins facilitate activation of latent TGF-β in the ECM, coupling mechanical cues to fibroblast stimulation. Targeting these integrins with therapies such as Bexotegrast attenuates local TGF-β activation, reduces fibroblast proliferation, and slows matrix stiffening, while minimizing systemic immunosuppressive effects

Growth factor receptors and kinases, including PDGF and fibroblast growth factor (FGF) receptors, drive fibroblast survival and expansion in fibrotic tissues. Small molecule inhibitors like Nintedanib block these pathways, limiting fibroblast proliferation and ECM accumulation. Across all fibrotic organs, this approach reduces parenchymal crowding and stabilizes tissue architecture.

Fibrosis is further reinforced by mechano-transduction and matrix stiffness pathways. ECM stiffening activates integrins and mechanosensitive transcriptional coactivators, including YAP/TAZ, forming a self-perpetuating profibrotic loop. Targeting these pathways with LOXL2 inhibitors (e.g., Simtuzumab) or YAP/TAZ modulators reduces crosslinking, lowers matrix rigidity, and restores fibroblast plasticity, effects that are relevant across lung, liver, kidney, cardiac, and dermal fibrosis.

Immune modulation and cytokine targets represent conserved profibrotic mechanisms, as cytokines such as IL-13 and IL-11 drive fibroblast activation in multiple fibrotic contexts. Therapeutics like Lebrikizumab or IL-11 receptor antagonists disrupt these paracrine loops, attenuating fibroblast activation, reducing inflammation, and limiting ECM deposition.

Finally, metabolic and regulated cell death pathways intersect with fibrosis universally. Agents modulating mitochondrial function or ferroptosis restore apoptotic sensitivity and limit myofibroblast persistence, thereby promoting tissue resolution and slowing organ remodeling.

In summary, these therapeutic targets, TGF-β / SMAD signaling, integrins, growth factor receptors, mechano-transduction pathways, profibrotic cytokines, and metabolic/cell death regulators, represent conserved mechanisms common to essentially all fibrotic diseases. Targeting them provides a framework for broad-spectrum antifibrotic therapy, applicable across organ systems.

Table 1. Conserved Therapeutic Targets in Fibrotic Diseases: Drug Modalities and Pathophysiological Consequences

Cell Based Assays for Fibrotic Disease Drug Discovery

Mechanism-based in vitro assays provide a critical foundation for understanding the cellular and molecular drivers of fibrotic diseases and for identifying therapeutic strategies that can effectively target these pathways.  By incorporating physiologically relevant culture conditions, these assays capture key aspects of fibrosis in a controlled setting. This approach enables high-fidelity mechanistic interrogation, facilitates identification of pathway-specific inhibitors, and allows prioritization of compounds with potential translational impact.

Below are in vitro cell-based assays for measuring key conserved, physiologically relevant functions in fibrotic diseases.

Activated Myofibroblasts

TGF-β–Induced Myofibroblast Differentiation (α-SMA Readout)

• This assay quantifies the extent to which fibroblasts transition into contractile α-SMA–positive myofibroblasts, a central driver of pathological tissue stiffening and scar formation in fibrosis.
• Basic assay description: Primary fibroblasts or fibroblast cell lines are stimulated with TGF-β, and α-smooth muscle actin (α-SMA) expression is measured by immunofluorescence, Western blot, or qPCR.

Collagen Gel Contraction Assay

• This assay measures the contractile function of activated myofibroblasts, reflecting their ability to remodel and mechanically stiffen extracellular matrix during fibrotic progression.
• Basic assay description: Fibroblasts are embedded in a 3D collagen gel matrix, and gel diameter or area reduction over time is quantified as a measure of cell-mediated contraction.

Excess ECM Deposition

Collagen Secretion Quantification

• This assay quantifies extracellular collagen production, directly modeling the excessive ECM accumulation characteristic of fibrotic lesions.
• Basic assay description: Collagen levels in culture supernatant or deposited matrix are measured using assays such as hydroxyproline quantification, ELISA, or Sirius Red staining.

Persistent Profibrotic Signaling

SMAD2/3 Reporter Assay

• This assay measures canonical TGF-β pathway activation, a central signaling axis sustaining fibroblast activation and fibrotic gene expression.
• Basic assay description: Cells are transfected with a SMAD-responsive luciferase reporter construct, stimulated with TGF-β, and luciferase activity is quantified.

PDGFR Signaling Assay

• This assay evaluates PDGFR-driven proliferative and survival signaling that promotes fibroblast expansion in fibrotic tissues.
• Basic assay description: Fibroblasts are stimulated with PDGF ligands, and receptor phosphorylation and downstream signaling (e.g., ERK/AKT activation) are measured by Western blot or ELISA.

Macrophage Reprogramming

M2 Polarization Assay

• This assay assesses macrophage skewing toward a profibrotic M2 phenotype that promotes fibroblast activation and ECM deposition.
• Basic assay description: Monocyte-derived macrophages are stimulated with IL-4/IL-13, and expression of M2 markers (e.g., CD206, Arg1) is quantified by flow cytometry or qPCR.

Macrophage–Fibroblast Co-Culture Assay

This assay models paracrine crosstalk between macrophages and fibroblasts that sustains chronic profibrotic activation.

Basic assay description: Macrophages and fibroblasts are cultured together (directly or via transwell), and fibroblast activation markers such as α-SMA and collagen are measured.

Epithelial/Endothelial Dysfunction & Senescence

Cellular Senescence Assay

This assay measures accumulation of senescent cells that contribute to fibrosis through persistent secretion of profibrotic SASP factors.

Basic assay description: Cells are stressed (e.g., oxidative stress, irradiation), and senescence markers such as SA-β-gal activity, p16^INK4a, or p21 expression are quantified.

EMT Assay

• This assay evaluates epithelial-to-mesenchymal transition (EMT), a process contributing to fibroblast-like cell accumulation and tissue remodeling in fibrosis.
• Basic assay description: Epithelial cells are treated with TGF-β or other stimuli, and loss of epithelial markers (e.g., E-cadherin) and gain of mesenchymal markers (e.g., vimentin) are assessed.

Mechanical Memory & Matrix Stiffness

YAP/TAZ Nuclear Translocation Assay

• This assay measures mechano-transduction signaling in response to matrix stiffness, which reinforces persistent fibroblast activation in fibrotic tissue.
• Basic assay description: Cells are cultured on substrates of defined stiffness, and nuclear versus cytoplasmic localization of YAP/TAZ is quantified by immunofluorescence imaging.

Apoptosis Resistance

Fibroblast Apoptosis Sensitization Assay

• This assay evaluates resistance of activated fibroblasts to apoptosis, a key mechanism underlying their persistence in fibrotic lesions.
• Basic assay description: Fibroblasts are treated with apoptotic stimuli (e.g., Fas ligand, staurosporine), and apoptosis is quantified using caspase activity assays or Annexin V staining.

Collectively, in vitro cell-based assays capture the complexity and heterogeneity of fibrotic disease. By providing direct, quantifiable readouts these systems enable robust screening and mechanistic dissection of potential therapeutics.

Conclusion

Fibrosis represents a conserved pathological program across organs, defined by persistent myofibroblast activation, excessive extracellular matrix deposition, immune–stromal crosstalk, mechano-transductive reinforcement, and failure of resolution pathways that together drive progressive organ dysfunction. Although initiating insults differ, the downstream fibroproliferative mechanisms are highly shared, creating a strong rationale for cross-indication therapeutic strategies. In this framework, mechanism-based in vitro cell assays are central to antifibrotic drug discovery, enabling controlled and scalable interrogation of core disease phenotypes, within human-relevant systems. By prioritizing functional reversal of conserved fibrotic states rather than simple target engagement, these platforms enhance translational predictability and accelerate identification of disease-modifying candidates. Continued refinement of physiologically relevant patient-informed in vitro models will be critical to bridging conserved fibrotic biology with effective therapeutic development.

References

1. Florian Rieder et al. Fibrosis: cross-organ biology and pathways to development of innovative drugs. Nat Rev Drug Discov. 2025;24:543–569.
2. Manyu Zhao et al. Targeting fibrosis: mechanisms and clinical trials. Signal Transduct Target Ther. 2022;7:206.
3. Jörg H W Distler et al. Mechanisms of fibrotic tissue remodeling: insights from systemic sclerosis. Nat Rev Rheumatol. 2026 (in press).

Disclaimer: This blog post is intended solely for educational and scientific informational purposes. Any mention of therapeutic drug names, including FDA-approved medications, is for the purpose of accurate reporting and discussion of biomedical research and does not constitute medical advice, endorsement, or promotion. Readers should not interpret the content as a recommendation for any specific treatment. Always consult a qualified healthcare professional for medical advice or treatment decisions.

About Marin Biologic Laboratories

Our Recent Publication/Meeting Presentation on Gene Therapy

1. Development of VNX-101, an Adeno-Associated Virus with Less Immunogenicity and Efficient Long-Term Expression of a CD19 T-Cell Engager. Molecular Therapy Methods & Clinical Development, published online July 24, 2025.

3. Cell-Based Potency Assay for Anti-CD3-Anti-CD19 Diabody. Journal of Immunological Methods. 2025. 545-114004.

3. Development of a Pharmacokinetic (PK) Mouse Serum GLP ELISA for an Anti–CD19–AntiCD3 Diabody
bioRxiv 2025.03.19.644217; doi: https://doi.org/10.1101/2025.03.19.644217.

4. American Society of Hematology (ASH) Annual Meeting 2024.
Abstract link: Using Gene Therapy to Solve Challenges with CAR-T Cell Immunotherapy: Lead Selection and Preclinical Development of an Adeno-Associated Virus with Reduced Immunogenicity Exhibiting Efficient and Long-Term Expression of an Anti-CD19 T-Cell Engager.

Comprehensive Assay Solutions for In Vitro and Cell Based Potency Assays and Pharmacokinetics Studies- Our Expertise

With 30 years of expertise in cell culture, cell-based assays, and preclinical/clinical PK/PD analysis, we specialize in offering assay services essential for a wide variety of therapeutic drug development programs, preclinical studies, IND/BLA applications, and commercialization. Our comprehensive services include both preclinical non-GLP and GLP assays, as well as non-GMP and GMP assays, providing critical support throughout the entire development pipeline.

Watch the following video and explore our latest presentation on the development and validation of potency and pharmacokinetic (PK) assays for AAV vectors, highlighting innovative methodologies and industry-leading expertise.

Download the full presentation: Development of Custom Cell Based and In vitro Potency and Pharmacokinetics (PK) Assays for AAV vectors- Marin biologic Laboratories

Development of Cell-Based Potency Assays: Case Studies and Blogs from Marin Biologic Laboratories (MarinBio)

Drug Discovery & Development Assays Offered by Marin Biologic Laboratories (MarinBio)

• ADME/Tox
• Molecular Biology
• The Art of Cell Culture
• Exosomes
• Stability Services
• Potency Assay
• Gene Therapy Assays
• Immunotherapy Assays
• Antiviral Therapy Assays
• cGMP
• MLR
• Cell Based Assays
• ELISA
• Flow Cytometry
• Protein
• PCR-qPCR
• Immunoassay
• Radioimmunoassay
• GLP
• Transfection
• Cell Therapy Assays
• Targeted Protein Degradation
• Research to Commercialization